Related Experiment Video
Updated: Nov 8, 2025
10:28
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
5.5K
Lipid-lowering therapy and percutaneous coronary interventions
Konstantinos C Koskinas1, François Mach, Lorenz Räber
1Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland.
Summary
Intensive reduction of low-density lipoprotein cholesterol (LDL-C) after percutaneous coronary interventions (PCI) significantly lowers recurrent cardiovascular events. Early statin therapy and adherence to lipid-lowering treatments are crucial for long-term patient benefit.
Area of Science:
- Cardiology
- Interventional Cardiology
- Lipidology
Background:
- Percutaneous coronary interventions (PCI) improve outcomes, but residual cardiovascular events persist.
- These events often stem from untreated non-culprit lesions and systemic pro-atherogenic factors.
- Suboptimal control of cardiovascular risk factors, particularly low-density lipoprotein cholesterol (LDL-C), drives residual risk.
Purpose of the Study:
- To review the role of LDL-C in coronary atherosclerosis development and progression.
- To discuss the clinical benefits of intensive lipid-lowering therapies post-PCI.
- To present current guideline recommendations for lipid management in patients undergoing PCI.
Main Methods:
- Review of current evidence on LDL-C's role in coronary atherosclerosis.
- Analysis of clinical benefits derived from intensive lipid-lowering treatments.
- Summary of current guideline recommendations for lipid management in cardiovascular disease.
Main Results:
- Lowering LDL-C levels halts coronary atherosclerosis progression and improves cardiovascular outcomes.
- The magnitude of LDL-C reduction is directly proportional to cardiovascular outcome improvement.
- Early, intensive statin therapy initiated during hospitalization provides early clinical benefit post-acute coronary syndrome (ACS).
Conclusions:
- Achieving guideline-recommended LDL-C goals is a priority for all physicians treating coronary heart disease.
- Comprehensive lipid-lowering strategies, including statins and non-statin drugs, should be initiated during in-hospital care for patients undergoing PCI.
- Prolonged adherence to optimized lipid-lowering treatment significantly reduces longer-term cardiovascular events following PCI.
Related Concept Videos
01:27Peripheral Artery Disease III: Interprofessional Care
96
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
96
01:27Coronary Artery Disease V: Interprofessional Care
105
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
105
01:26Atherosclerosis III: Management
97
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
97
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.1K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K
01:26Angina IV: Management
105
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
105
01:28Acute Coronary Syndrome IV: Interprofessional Care
74
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
74